


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

ADAMS *et al.*

Appl. No. 08/549,318

Filed: October 27, 1995

For: **Boronic Ester and Acid
Compounds, Synthesis and Uses**

Art Unit: (To Be Assigned)

Examiner: (To Be Assigned)

Atty. Docket: 1448.0120002/JAG/JMC

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants in compliance with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents AS1, AT1, AM3, AO3, AP4, AR4, AS4, AT4, AL5, AS5, AT5, AR8, AT8, AR9 and AS9 are also included herewith.

Pursuant to 37 C.F.R. § 1.98(d), all other documents cited on this Form PTO-1449 were cited by the Examiner, or were previously cited and copies submitted in Applicants' 35 U.S.C. § 120 priority Application Nos. **08/330,525**, filed **October 28, 1994**, and **08/442,581**, filed **May 16, 1995**; copies of these documents should already be on file at the PTO and are therefore not included herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following concise explanations of the relevance of the non-English language documents, Reference Numbers AO1, AP1, AL2 and AO5, cited on the Form PTO-1449:

Reference AO1, European patent application EP 0 315 574, Kleeman *et al.*, discloses α -amino boronic acid derivatives that inhibit the action of the enzyme renin.

Reference AP1, European patent application EP 0 354 522, Mölling *et al.*, is equivalent to its priority document, German patent document DE 38 27 340, cited herein as Reference AL2. These documents disclose the use of aminomethyl-boronate ester derivatives for treating viral infections.

Reference AO5, PCT published application number WO 94/23045, Baeuerle *et al.*, discloses the inhibition of NF- κ B activation for the treatment of pathological conditions due to undesired gene expression. In accordance with 37 C.F.R. § 1.98(c), an English translation of this application was included as Reference AP4 in Applicants' Information Disclosure Statement filed on June 26, 1995, in U.S. Application No. 08/442,581, the parent of the instant application, and is therefore neither cited nor included herewith.

Applicants also wish to call the Examiner's attention to co-pending, commonly owned U.S. Application Nos. ^{18N}08/210,381, filed March 18, 1994, and ¹¹⁸¹08/404,866, filed March 15, ^{1817 Prickril}1995, which are directed to related subject matter. ^{7111 Johnson}

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application.

This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made. It is understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.


Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

It is believed that no fees are due for consideration of this Information Disclosure

Statement. Any fees which may be due may be debited to our Deposit Account No. 19-0036. A duplicate copy of this statement is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert
Attorney for Applicants
Registration No. 38,759

Date: April 8, 1996

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600